Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
14.39
-0.27 (-1.84%)
At close: Aug 13, 2026, 4:00 PM EDT
14.30
-0.09 (-0.63%)
Pre-market: Aug 14, 2026, 8:25 AM EDT
Design Therapeutics Employees
Design Therapeutics had 55 employees as of June 30, 2026. The number of employees decreased by 2 or -3.51% compared to the same quarter last year.
Employees
55
Change
-2
Growth
-3.51%
Revenue / Employee
n/a
Profits / Employee
-$1,287,182
Market Cap
900.55M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 55 | -2 | -3.51% | 55 | 0 |
| Mar 31, 2026 | 54 | -2 | -3.57% | 54 | 0 |
| Dec 31, 2025 | 54 | 0 | - | 54 | 0 |
| Sep 30, 2025 | 55 | 1 | 1.85% | 55 | 0 |
| Jun 30, 2025 | 57 | 0 | - | 57 | 0 |
| Mar 31, 2025 | 56 | -1 | -1.75% | 56 | 0 |
| Dec 31, 2024 | 54 | -4 | -6.90% | 54 | 0 |
| Sep 30, 2024 | 54 | -3 | -5.26% | 54 | 0 |
| Jun 30, 2024 | 57 | -11 | -16.18% | 57 | 0 |
| Mar 31, 2024 | 57 | -7 | -10.94% | 57 | 0 |
| Dec 31, 2023 | 58 | 0 | - | 58 | 0 |
| Sep 30, 2023 | 57 | 1 | 1.79% | 57 | 0 |
| Jun 30, 2023 | 68 | 16 | 30.77% | 68 | 0 |
| Mar 31, 2023 | 64 | 20 | 45.45% | 64 | 0 |
| Dec 31, 2022 | 58 | 20 | 52.63% | 58 | 0 |
| Sep 30, 2022 | 56 | 23 | 69.70% | 56 | 0 |
| Jun 30, 2022 | 52 | 27 | 108.00% | 51 | 1 |
| Mar 31, 2022 | 44 | 23 | 109.52% | 44 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Kura Oncology | 260 |
| Geron | 258 |
| Omeros | 175 |
| Olema Pharmaceuticals | 150 |
| Solid Biosciences | 121 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
DSGN News
- 11 days ago - Design Therapeutics reports Q2 EPS (32c), consensus (34c) - TheFly
- 11 days ago - Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 11 days ago - Design Therapeutics Quarterly report: Q2 2026 - Filings
- 11 days ago - Design Therapeutics Earnings release: Q2 2026 - Filings
- 6 weeks ago - Design Therapeutics initiates patient dosing in DT-818 trial - TheFly
- 6 weeks ago - Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 - GlobeNewsWire
- 2 months ago - Design Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Design Therapeutics Slides: Corporate presentation - Filings